Cargando…

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the intrahepatic bile ducts. Currently, the first line drug for PBC is ursodeoxycholic acid (UDCA) characterized by anti-apoptotic, anti-inflammatory and protective actions on chol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abenavoli, Ludovico, Procopio, Anna Caterina, Fagoonee, Sharmila, Pellicano, Rinaldo, Carbone, Marco, Luzza, Francesco, Invernizzi, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348889/ https://www.ncbi.nlm.nih.gov/pubmed/32532037 http://dx.doi.org/10.3390/diseases8020020

Ejemplares similares

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Anxiety and Gastrointestinal Symptoms Related to COVID-19 during Italian Lockdown
por: Abenavoli, Ludovico, et al.
Publicado: (2021)

Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic
por: Scarpellini, Emidio, et al.
Publicado: (2020)

The Evolving Incidence of Hepatitis C Virus Infection in Italy
por: Pellicano, Rinaldo, et al.
Publicado: (2012)

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

Promises of Fibroblast Growth Factor Receptor–Directed Therapy in Tailored Cancer Treatment
por: Fagoonee, Sharmila, et al.
Publicado: (2020)

Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?
por: Fagoonee, Sharmila, et al.
Publicado: (2019)

A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis
por: Manno, Valerio, et al.
Publicado: (2019)

The Role of Epigenetics in Primary Biliary Cholangitis
por: Gerussi, Alessio, et al.
Publicado: (2022)

Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation
por: Etherington, Rachel E., et al.
Publicado: (2019)

Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2021)

Trends in the Comprehension and Management of Gastrointestinal Tract Disorders
por: Durazzo, Marilena, et al.
Publicado: (2022)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
por: Lleo, Ana, et al.
Publicado: (2016)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)
por: Pierre, Joseph F., et al.
Publicado: (2019)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
por: Erken, Robin, et al.
Publicado: (2021)

Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial
por: Jones, David, et al.
Publicado: (2023)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

New insights on the role of human leukocyte antigen complex in primary biliary cholangitis
por: Mulinacci, Giacomo, et al.
Publicado: (2022)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

Comment on “Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis”
por: Cristoferi, Laura, et al.
Publicado: (2020)

Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome
por: Pereira-Fantini, Prue M., et al.
Publicado: (2017)

Helicobacter pylori and Respiratory Diseases: 2021 Update
por: Durazzo, Marilena, et al.
Publicado: (2021)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
por: Colapietro, Francesca, et al.
Publicado: (2023)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo
por: Hassan, Haider M., et al.
Publicado: (2022)

Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis
por: Lleo, Ana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dvsl3dqss0iat6pvbiqb12mpr9